Can Ozempic Cause Muscle Loss? What the Research Actually Says

When semaglutide — sold under the brand names Ozempic and Wegovy — first started making headlines for its dramatic weight loss results, most of the conversation focused on the number on the scale. What received far less attention was what, exactly, was being lost. A 2024 narrative review published in Diabetes Care put the issue in sharp relief: GLP-1 receptor agonists like semaglutide cause rapid and significant loss of lean mass — roughly 10% of total body weight, or about 6 kilograms — an amount comparable to more than a decade of normal aging-related muscle decline. That’s not a side effect buried in the fine print. That’s a central physiological consequence that every man on these medications needs to understand.

The question isn’t whether Ozempic can cause muscle loss. The evidence says it can. The more important question is what drives it, who is most at risk, and what you can do to protect the muscle you’ve spent years building — or are just starting to build.

Why Ozempic Leads to Muscle Loss — and Who Bears the Most Risk

Semaglutide works primarily by mimicking glucagon-like peptide-1, a gut hormone that regulates appetite and insulin secretion. The result is a significant reduction in caloric intake. And here’s the biological reality that doesn’t discriminate between medications and traditional diets: when you’re in a sustained caloric deficit, your body doesn’t just burn fat. It draws on lean tissue as well. The more aggressive the deficit, the more lean mass tends to go with it. Ozempic accelerates weight loss, which means it can accelerate this trade-off if nothing is done to counteract it.

The concern is significantly amplified in older men. A 2025 retrospective cohort study published in Drug Design, Development and Therapy followed 220 older adults with type 2 diabetes on semaglutide for 24 months and found that semaglutide treatment significantly reduced both body mass index and muscle mass compared to matched controls, with gait speed declining in both men and women and grip strength eventually dropping in men after an initial improvement. Higher doses were independently associated with greater muscle loss, and the effect was most pronounced in patients who already had low muscle mass going in.

This matters enormously in the context of sarcopenic obesity — a condition where reduced skeletal muscle mass coexists with excess body fat. Research published in Diabetes in 2025 estimates that sarcopenic obesity affects roughly 28% of adults over 60, and aging accelerates the problem through hormonal shifts, metabolic changes, and reduced physical activity. For this population especially, the authors argue that GLP-1 medications need to be used cautiously, with careful patient selection, ongoing monitoring, and active countermeasures in place.

For younger, active men, the risk profile looks different — but it’s not zero. Even if you’re 35, training regularly, and eating well, a significant caloric suppression without deliberate protein and resistance training strategies can chip away at the lean mass you’ve built. The mechanism is the same regardless of age; the stakes just get higher as you get older.

What You Can Do to Protect Your Muscle While on Semaglutide

The good news is that the same review in Diabetes Care that documented the lean mass losses also pointed clearly toward a solution. Supervised resistance training programs lasting more than 10 weeks produced meaningful gains in lean mass — around 3 kilograms — and strength improvements of approximately 25% in men and women. That won’t fully offset the lean mass losses from GLP-1 therapy on its own, but it dramatically changes the trajectory. Combining aerobic exercise with liraglutide also improved long-term weight loss maintenance compared to either intervention alone, suggesting that exercise amplifies the benefits of the medication rather than simply undoing its downsides.

The practical implication is straightforward: if you’re on Ozempic or any GLP-1 medication, resistance training is not optional. It’s the primary tool for preserving the muscle you’d otherwise lose. Compound movements — squats, deadlifts, rows, presses — trained with sufficient intensity and frequency (three to four sessions per week is a reasonable starting point) are what the literature supports. Progressive overload, meaning consistently challenging the muscle over time, is what drives the adaptation.

Protein intake becomes equally critical. When calories are suppressed, getting enough protein requires deliberate effort. Most research supports a target of 1.6 to 2.2 grams of protein per kilogram of bodyweight for men focused on preserving or building muscle during a caloric deficit. Foods like eggs, chicken, salmon, Greek yogurt, and lean beef should anchor each meal. If appetite suppression makes hitting that target difficult — a common experience on semaglutide — a high-quality protein supplement can serve as a practical bridge, not a replacement for whole foods.

Sleep and recovery also play a role that often gets underestimated. Growth hormone secretion, muscle protein synthesis, and testosterone regulation all depend on adequate sleep quality and duration. Seven to nine hours isn’t a luxury — it’s part of the physiological environment that determines whether resistance training actually produces muscle retention or just exhaustion.

The broader picture emerging from the research landscape is that GLP-1 medications like semaglutide offer substantial benefits well beyond weight loss. A 2026 review in The Lancet Diabetes & Endocrinology synthesized evidence across cardiovascular disease, liver disease, kidney disease, sleep apnea, depression, and more, concluding that GLP-1-based therapies show beneficial effects across a wide range of obesity-related conditions, with some effects appearing independent of weight loss itself. The cardiac data is particularly compelling — a 2024 study in Nature Communications demonstrated that semaglutide improved cardiac function and preserved mitochondrial structure in a mouse model of heart failure, partly by optimizing how the heart metabolizes energy substrates. These are meaningful findings. They don’t eliminate the concern about muscle loss, but they contextualize it: these medications do real good, and that good needs to be weighed against the risks.

The critical insight is that muscle loss on semaglutide is not inevitable — it’s the default outcome when the medication is used without a structured exercise and nutrition plan. For men who are already training, eating sufficient protein, and managing recovery, the risk is substantially reduced. For men who are sedentary or already at risk for low muscle mass, particularly those over 50, the approach requires more deliberate planning and medical supervision.

The Takeaway

Ozempic and semaglutide are powerful tools. They produce real, clinically meaningful weight loss. They reduce cardiovascular risk, improve metabolic markers, and benefit multiple organ systems. But the research is equally clear that without active countermeasures, a significant portion of the weight lost will come from lean muscle — not just fat. For men, where muscle mass is directly tied to metabolic health, physical function, hormonal balance, and long-term quality of life, that’s a trade-off worth taking seriously. The answer isn’t to avoid the medication if it’s appropriate for your situation. The answer is to earn your muscle back — and keep it — through resistance training, adequate protein, and the kind of consistent effort that no prescription can replace.